Navigation Links
CardioGenics to be Spotlighted in Three Publications During Month of April
Date:4/22/2010

eet Transcript website on April 5, 2010, Dr. Gawad provides a brief history of CardioGenics, describes why he chose to enter the In Vitro Diagnostics market, and provides additional details on the status of the QL Care analyzer. He highlights some of the challenges of securing the medical community's acceptance of new technology and of doing business during a time when US healthcare options are being dramatically overhauled.      

Dr. Gawad remarked: "As CardioGenics continues to grow and to prepare its products for market, we welcome media attention that focuses on what we have to offer the healthcare community. We believe our QL Care analyzer and other products offer the possibility of saving many lives, and such exposure allows potential customers to become aware of our technology and how it could serve their patients."

To read the Today's Medical Developments article, please visit: http://www.onlinetmd.com/tmd-0410-test-results-improves-diagnosis.aspx

To read the Medical Design Technology article, please visit:  

http://e-ditionsbyfry.com/Olive/ODE/MDT/ and click on p. 20 in the Table of Contents

To read an excerpt of The Wall Street Transcript Q&A, please visit:


SOURCE CardioGenics Holdings Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. CardioGenics Holdings Inc. Provides Update on FINRA Submission Regarding Name Change
2. CardioGenics Holdings Inc. Announces Letter to Shareholders
3. CardioGenics Announces Completion of Cartridge Design for QL Care Analyzer
4. CardioGenics Holdings Inc. Featured in Medical Device Daily
5. Dr. Yahia Gawad, CEO of CardioGenics Holdings, Inc., Interviewed in MedTech Executive
6. CardioGenics Provides Update on Agreement with Merck Chimie for Its Silver Coated Paramagnetic Beads
7. CardioGenics Announces Further Update Regarding Status of Merck Agreement
8. CardioGenics Announces Lock-Up Agreement with Dr. Yahia Gawad
9. ViroPharma to Present at Three Upcoming Healthcare Conferences
10. Four Analyses of Three-Year Clinical Data Suggest CYPHER(R) Sirolimus-Eluting Coronary Stent May Provide Alternative to Surgery for Patients with Multivessel Disease
11. Versatility of 454 Sequencing(TM) Demonstrated in Three Publications in Science Last Week
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... 2014 Amgen (NASDAQ: AMGN ) ... 2014. Key results include: , Total revenues increased ... sales growth driven by strong performance across the portfolio, ... Prolia ® (denosumab) and XGEVA ® (denosumab). ... driven by higher revenues and a significant increase in ...
(Date:7/29/2014)... July 29, 2014 Regado Biosciences, Inc. (Nasdaq: ... the Phase 3 clinical development of Revolixys™ Kit (previously ... system, today announced that it will hold a conference ... 2014, at 8:30 a.m. EDT to discuss its second ... Interested participants and investors may access the conference call ...
(Date:7/29/2014)...  EnteroMedics Inc. (NASDAQ: ETRM ), the ... obesity, metabolic diseases and other gastrointestinal disorders, today announced ... August 7, 2014 at 11:00 AM Eastern Time to ... 30, 2014 and to provide a business update. ... conference call may be accessed by dialing (877) 280-7473 ...
Breaking Medicine Technology:Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 2Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 3Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 4Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 5Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 6Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 7Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 8Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 9Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 10Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 11Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 12Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 13Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 14Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 15Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 16Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 17Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 18Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 19Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 20Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 21Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 22Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 23Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 24Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 25Regado Biosciences to Provide Second Quarter 2014 Financial Results and Corporate Highlights 2Regado Biosciences to Provide Second Quarter 2014 Financial Results and Corporate Highlights 3EnteroMedics to Host Second Quarter 2014 Financial Results and Business Update Conference Call 2EnteroMedics to Host Second Quarter 2014 Financial Results and Business Update Conference Call 3
... 27, 2011 A milestone in lupus research was met this ... Research (ALR) held its 8th annual New York City Walk ... Park was matched by the enthusiasm of the nearly 3000 walkers ... by NYC master of ceremonies, My9 news anchor Brenda Blackmon, ALR ...
... 27, 2011   FHSSA counts its partnership initiative ... known as the Foundation for Hospices in Sub-Saharan ... between US hospice programs and organizations providing care ... assistance, support and friendship.  They are working collaboratively ...
Cached Medicine Technology:Alliance for Lupus NYC Walk With Us to Cure Lupus First Lupus Walk In History To Raise $1-Million 2FHSSA Launches New Campaign to Partner US Hospices with Programs in Sub-Saharan Africa 2
(Date:7/29/2014)... Perth WA, Australia (PRWEB) July 30, 2014 ... and regulation of medical devices have determined Nurse ... Australian and international legislation, this requires all Nurse ... certified. This regulatory practice improves patient safety, reduces ... State and private hospital based Corporate Risk and ...
(Date:7/29/2014)... Daily Gossip indicates in its Natural Vitiligo Treatment ... a popular nutritionist and health specialist. Michael Dawson suffered ... disorder, but none of them worked. , According to ... to look for an alternative vitiligo treatment, which he ... too, to become vitiligo free. , To learn ...
(Date:7/29/2014)... Advertising claims for cosmetic procedures using stem cells ... safety and effectiveness, according to a review in the ... , the official medical journal of the ... cells offer tremendous potential, but the marketplace is saturated ... patients at risk," write Dr Michael T. Longaker of ...
(Date:7/29/2014)... 29, 2014 According to a July ... Magazine titled “From Kim’s Butt to Angelina’s Lips: The ... butt is the celebrity feature most requested by women ... Beyoncé’s butt, Jennifer Lawrence’s nose, and ... based on data collected by an online community focused ...
(Date:7/29/2014)... New York (PRWEB) July 29, 2014 ... behalf of individuals who allegedly suffered serious liver ... continue to move forward in a multidistrict litigation ... Pennsylvania, Bernstein Liebhard LLP reports. According to an ... certain deadlines pertaining to bellwether case and ...
Breaking Medicine News(10 mins):Health News:NiQ Health Reveals the Extensive Use of Unregulated Medical Devices in Australian Hospitals 2Health News:NiQ Health Reveals the Extensive Use of Unregulated Medical Devices in Australian Hospitals 3Health News:NiQ Health Reveals the Extensive Use of Unregulated Medical Devices in Australian Hospitals 4Health News:Natural Vitiligo Treatment System Review Reveals Michael Dawson’s New Vitiligo Cure Program 2Health News:Beware of claims about cosmetic stem cells procedures, says review in Plastic and Reconstructive Surgery 2Health News:Celebrity Plastic Surgery: Kim Kardashian’s Butt Tops the List of Celebrity Plastic Surgery Requests 2Health News:Tylenol Lawsuit News: Federal Court Overseeing Tylenol Liver Damage Claims Sets New Deadlines Pertaining to Discovery, Bellwether Trials, Bernstein Liebhard LLP Reports 2Health News:Tylenol Lawsuit News: Federal Court Overseeing Tylenol Liver Damage Claims Sets New Deadlines Pertaining to Discovery, Bellwether Trials, Bernstein Liebhard LLP Reports 3Health News:Tylenol Lawsuit News: Federal Court Overseeing Tylenol Liver Damage Claims Sets New Deadlines Pertaining to Discovery, Bellwether Trials, Bernstein Liebhard LLP Reports 4
... people with mood disorders who have attempted suicide are more ... The link is especially strong among those who have been ... disorders themselves. ,Research has shown people with a family ... but few studies have looked at the factors that put ...
... internet-based learning exercise has helped a group of doctors ... Many people take herbs and other dietary supplements, but ... complementary medicines. A group called the Longwood Herbal Task ... School and other prestigious US medical centres, has set ...
... Urological Association,k overweight men are more likely to suffer ... men surveyed between the ages of 50 and 85 ... were more likely to be older, have high blood ... waistline measuring 40 inches were nearly twice as likely ...
... promoted a marked reduction in the use of indwelling catheters. ... walked into a geriatric ward or nursing home in the ... smell. Urinary incontinence is common among the very old, but ... Anyhow, much progress has been made and, in fact, an ...
... with a higher dose of radiotherapy, with weekends off ... dose of radiotherapy five days a week, for six weeks.// ... programme known as CHART which uses three doses a day ... Middlesex, England, have taken CHART further. ,Using computer ...
... and Danish have discovered a way to prevent ... they believe may bring a string of benefits ... to cleaner contact lenses.// The discovery, by scientists ... Bioscience and the Technical University of Denmark, was ...
Cached Medicine News:Health News:Bacterial discovery may help CF patients 2
Endoscopes are also available in fully autoclavable models in 1.8, 2.7, 4.0. 5.0 and 10.0 mm diameters. Manufactured with precise swiss lenses. Built-in temperature measuring device to exactly determ...
Endoscopes are also available in fully autoclavable models in 1.8, 2.7, 4.0. 5.0 and 10.0 mm diameters. Manufactured with precise swiss lenses. Built-in temperature measuring device to exactly determ...
Kleinert-Kutz Single Skin Hook, Large...
Designated most popular model or size....
Medicine Products: